blank blank blank blank blank



Pain is the leading cause of patient visits to their doctors. It is impacting the daily lifes of more than 70 million Americans every year, and pain is increasingly viewed as an illness in itself, not merely a symptom of an underlying disease process.

Safe and effective treatment of pain remains a key challenge facing the patient and health care professionals everywhere. Currently available pain drugs are linked to substantial risk of adverse effects. NSAID use alone is the direct cause of more than 100.000 hospitalizations and 30.000 deaths annually in the US. The costs to the health care system and the loss of patient welfare due to these side effects are huge.

SantoSolve is all about contributing to the pain treatment solution. Our approach is to use the element strontium to modulate pain signalling in the peripheral nerve system, exploiting strontiums function as a calcium antagonist in selected processes involved in the molecular pathways responsible for generation and transmission of the pain signal. We are developing topical pain treatments that are both safe and effective against various chronic pain conditions, including osteoarthritis of the knee.

SantoSolve's principal product, 2PX, has the potential to provide clinical benefit in the management of both nociceptive and neuropathic pain, and the development program is initially focused on osteoarthritis, specifically osteoarthritis of the knee. Osteoarthritis currently afflicts approximately 27 million people in the United States, up from the 1990 estimate of 21 million people, according to Arthritis & Rheumatism, January 2008 and National Arthritis Data Workgroup. Moreover, the number of people afflicted with osteoarthritis in the United States is expected to grow 40% until 2030. It is also estimated that an additional 27 million people in Europe suffer from osteoarthritis, according to a July 2007 Frost & Sullivam report. The current standard of care includes COX-2 inhibitors (Celebrex) and NSAIDs (naproxen, diclofenac). However, the clinical and commercial potential of COX-2 inhibitors has been substantially reduced due to significant negative cardiovascular safety reactions leading to the withdrawal of Vioxx and Bextra from the market. Similarly, NSAIDs have a "black box" safety warning in the United States for both gastrointenstinal side effects and cardiovascular issues. As a result, there is considerable favorable side effect profiles that address unmet medical need for efficacious products with the osteoarthritis market. Currently, there are a number of new formulations of older chemical entities in development to address this market. However, SantoSolve's 2PX represents the only product in late stage development that utilizes a completely new agent for pain management which has demonstrated promising efficacy coupled with an excellent safety profile.

In addition, the Company believes that 2PX will address a number of other significant market opportunities in the areas of both nociceptive and neuropathic pain. These areas include other osteoarthritis indications, other musculoskeletal pain indications and neuropathic pain indications such as post-herpetic neuralgia and chronic post-amputation pain (stump pain).

SantoSolve is a privately held company, located in Oslo, Norway.


Andres K. Flaaten
Kenneth G. Bern


Thorfinn Ege, PhD

SantoSolve AS

Enebakkveien 117A, 0680 Oslo
Ph: +47 21 95 07 34
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

blank blank blank blank blank
Copyright © SantoSolve AS Enebakkveien 117A, 0680 Oslo, Norway | Ph: +47 21 95 07 34 | post@santosolve.com Designed by moondesign as, developed by Sondre Nilsen